1 |
NCT00991224 |
Completed |
Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy |
|
- Biological: WT-gag-TCR modified T cells
- Biological: α/6-gag-TCR modified T cells
- Other: STI or Drug Holiday
|
Interventional |
Phase 1 |
- University of Pennsylvania
- Adaptimmune
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- To determine optimal dose and to evaluate the safety and tolerability of the study drug.
- To monitor for delayed adverse events associated with lentiviral vector gene transfer (RCL and insertional oncogenesis)
- To determine the antiviral effects of WT‐gag‐and α/6‐gag‐ TCR transduced cells in patients with low and high antigen load (presence and absence of viremia)
- To monitor engraftment of vector modified cells in the peripheral circulation
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT00991224 |
810108 |
|
November 2009 |
January 2014 |
January 2014 |
October 7, 2009 |
December 13, 2017 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
2 |
NCT00991354 |
Completed |
Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults |
|
- Biological: PENNVAX-B
- Biological: IL-12 DNA plasmids
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Frequency and severity of local injection/EP site reactogenicity signs and symptoms
- Magnitude of local injection/EP site pain as measured by a VAS
- Frequency of AEs categorized by MedDRA body system, MedDRA preferred term, severity and assessed relationship to study products; detailed description of all AEs meeting DAIDS criteria for expedited reporting
- (and 8 more...)
|
48 |
All |
18 Years to 50 Years (Adult) |
NCT00991354 |
HVTN 080 10741 |
|
November 2009 |
February 2011 |
March 2011 |
October 8, 2009 |
July 27, 2016 |
|
- Univ. of Rochester HVTN CRS
Rochester, New York, United States - 3535 Market Street CRS
Philadelphia, Pennsylvania, United States - Vanderbilt Vaccine CRS
Nashville, Tennessee, United States
|
3 |
NCT00995176 |
Completed |
The Women's HIV SeroIncidence Study (ISIS) |
|
|
Observational |
|
- HIV Prevention Trials Network
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Estimation of the overall HIV-1 incidence rate among 2,000 women in the US from defined geographic areas with high HIV prevalence and poverty
- Evaluation of laboratory assays for HIV-1 incidence determination
- Estimation of recruitment and retention rates
- (and 4 more...)
|
2099 |
All |
18 Years and older (Adult, Senior) |
NCT00995176 |
HPTN 064 1U01AI068619 |
|
April 2009 |
March 2011 |
March 2011 |
October 15, 2009 |
January 21, 2016 |
|
- George Washington University
Washington, District of Columbia, United States - The Ponce de Leon Center
Atlanta, Georgia, United States - Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, United States - (and 6 more...)
|
4 |
NCT00987948 |
Completed Has Results |
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels |
|
- Drug: maraviroc (Selzentry)
|
Interventional |
Phase 2 |
- University of Hawaii
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline to 24 Weeks in HIV DNA (Log-10 Copies/10^6 Cells) as Measured by HIV DNA Within CD14+ Peripheral Blood Mononuclear Cells
- Change From Baseline to 24 Weeks in Neuropsychological Performance As Measured by Age- and Education-Adjusted Z-Scores
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT00987948 |
H005 |
|
January 2010 |
November 2012 |
August 2013 |
October 1, 2009 |
March 22, 2017 |
March 22, 2017 |
- Hawaii Center for AIDS
Honolulu, Hawaii, United States
|
5 |
NCT00984971 |
Completed |
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet |
- HIV Prevention
- HIV Infections
|
- Drug: Tenofovir
- Drug: HEC Placebo
- Drug: Open label tenofovir tablet
|
Interventional |
Phase 1 |
- CONRAD
- National Institute of Allergy and Infectious Diseases (NIAID)
- Microbicide Trials Network
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Grade 2 or higher clinical and laboratory adverse events as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0,Dec 2004 and Addenda 1 and 3 to this table.
- Immunotoxicity, Pharmacokinetics, and Acceptability
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT00984971 |
DAIDS ID 10769 RMP02-MTN006 |
RMP02-MTN006 |
September 2009 |
June 2010 |
July 2010 |
September 25, 2009 |
August 28, 2015 |
|
- UCLA Center for HIV Prevention Research
Los Angeles, California, United States - University of Pittsburgh Clinical Research Unit
Pittsburgh, Pennsylvania, United States
|
6 |
NCT00990678 |
Completed |
Study of Vitamin D Supplementation to Male HIV Sero-positive Patients |
|
- Drug: Rocaltrol
- Drug: Vitamin D
- Drug: Calcium
|
Interventional |
Not Applicable |
- Hvidovre University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- serum-vitamin D metabolites
- T-lymphocyte fractions Parathyroid hormone ionized calcium
|
60 |
Male |
18 Years and older (Adult, Senior) |
NCT00990678 |
HH-JEBJ-HIVstudy EudraCT 2006-005039-40 Danish Health 2612-3303 |
|
April 2008 |
February 2010 |
January 2011 |
October 7, 2009 |
September 17, 2012 |
|
- Dept. of endocrinology, Hvidovre Hospital
Copenhagen, Denmark
|
7 |
NCT00987194 |
Completed |
HIV Testing in the Emergency Department at Baystate Medical Center: A Pilot Program |
|
|
Observational |
|
- Baystate Medical Center
- Massachusetts Department of Health
|
Other |
- Time Perspective: Prospective
|
- The feasibility of initiating a rapid HIV testing program in the emergency department of a community teaching hospital in an a medium size city.
- To determine the number of newly diagnosed individuals who were successfully linked to an HIV provider and the number who received antiretroviral therapy within one year of initial diagnosis.
|
1087 |
All |
18 Years and older (Adult, Senior) |
NCT00987194 |
IRB09-012 |
|
March 2009 |
March 2010 |
March 2010 |
September 30, 2009 |
July 14, 2010 |
|
- Baystate Medical Center
Springfield, Massachusetts, United States
|
8 |
NCT00995241 |
Completed |
Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV |
|
|
Interventional |
Phase 4 |
- Germans Trias i Pujol Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasmatic and intracellular concentration of raltegravir
- Clearance, CL/F
- Volume of distribution, V/F
- (and 5 more...)
|
5 |
All |
18 Years to 65 Years (Adult) |
NCT00995241 |
RAL-IC |
|
November 2009 |
December 2009 |
December 2009 |
October 15, 2009 |
September 10, 2010 |
|
- Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain - Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
|
9 |
NCT00998582 |
Terminated Has Results |
Artery Elasticity After Switch From Epzicom to Truvada |
|
- Drug: Tenofovir disoproxil
|
Interventional |
Phase 4 |
- Minneapolis Medical Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Small Artery Elasticity (mL/mmHg x100) From Baseline to Week 24
- Outcome Was Change in Large Artery Elasticity (mL/mmHg x100) From Baseline to Week 24
|
27 |
All |
18 Years and older (Adult, Senior) |
NCT00998582 |
PCC-004 |
|
October 2009 |
June 2011 |
December 2011 |
October 20, 2009 |
October 8, 2012 |
March 23, 2012 |
- Hennepin County Medical Center
Minneapolis, Minnesota, United States - Abbott Northwestern Hospital and Clinics
Minneapolis, Minnesota, United States
|
10 |
NCT01001741 |
Completed |
Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana |
|
- Other: Cell phone text message
|
Interventional |
Not Applicable |
- University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
|
128 |
All |
21 Years and older (Adult, Senior) |
NCT01001741 |
805891 NIH: P30 AI 045008 |
|
June 2008 |
August 2009 |
August 2009 |
October 27, 2009 |
September 17, 2015 |
|
- Independence Surgery
Gaborone, Botswana
|
11 |
NCT00994344 |
Completed |
Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens |
|
- Drug: Darunavir/ritonavir
- Drug: Lopinavir/ritonavir
|
Interventional |
Phase 4 |
- Germans Trias i Pujol Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasmatic HIV-1 Viral load
- CD4 cell count
- Changes in liver enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma GT, alkaline phosphatase)
- (and 9 more...)
|
73 |
All |
18 Years to 65 Years (Adult) |
NCT00994344 |
LOPIDAR |
|
October 2009 |
October 2012 |
October 2012 |
October 14, 2009 |
February 13, 2014 |
|
- Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain - Hospital Universitario de Canarias
Santa Cruz de Tenerife, Canarias, Spain
|
12 |
NCT00985647 |
Completed |
Pharmacokinetics of Lamivudine at Two Different Doses |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma concentrations of 3TC and intracellular concentrations of its active anabolite 3TC-TP as measured by the Area Under the Curve (AUC 0-24h).
- Safety and tolerability of 3TC following the administration of 3TC 300 mg and 150 mg once daily
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT00985647 |
NCHECR-ENCORE2 |
ENCORE2 |
December 2009 |
February 2010 |
March 2010 |
September 28, 2009 |
February 11, 2011 |
|
- St Stephen's Centre, Chelsea and Westminster Hospital
London, United Kingdom
|
13 |
NCT01001247 |
Completed |
TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers |
|
|
Interventional |
Phase 1 |
- Tibotec Pharmaceuticals, Ireland
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma levels of TMC278 assessed after co-administration of 20mg q.d. omeprazole taken either in the morning (1.5 h before TMC278) or in the evening (12 h before TMC278); assess 24h intragastric pH at days of intake of TMC278
- To evaluate the short-term safety and tolerability of co-administration of omeprazole with a single 25mg and 50mg dose of TMC278
|
18 |
All |
18 Years to 55 Years (Adult) |
NCT01001247 |
CR016267 |
|
January 2010 |
April 2010 |
April 2010 |
October 26, 2009 |
July 9, 2010 |
|
|
14 |
NCT00991302 |
Completed Has Results |
Durability of Adherence in Self-Management of HIV |
|
|
Interventional |
Not Applicable |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Self-reported Adherence Score (%) Over a One-month Recall
- Mean Self-reported Adherence Score Over a One-month Recall
- Kaplan-Meier Estimate of the Cumulative Probability of Time to Change of Initial Antiretroviral (ARV) Treatment Regimen for Any Reason by Week 48
- (and 3 more...)
|
172 |
All |
18 Years and older (Adult, Senior) |
NCT00991302 |
ACTG A5250 1U01AI068636 10654 |
DASH |
January 2010 |
January 2015 |
January 2015 |
October 8, 2009 |
March 20, 2018 |
August 26, 2015 |
- Ucsd, Avrc Crs
San Diego, California, United States - Barranco CRS (11301)
Lima, Peru
|
15 |
NCT00988442 |
Terminated Has Results |
Telephone Support to Improve Adherence to Anti-HIV Medications |
|
- Behavioral: Enhanced nursing telephone support
- Behavioral: Standard care
|
Interventional |
Phase 2 |
- AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Supportive Care
|
- Number of Participants With Virologic Suppression
- Number of Participants With Premature Antiretroviral Therapy (ART) Regimen Discontinuation
- Change in CD4 Cell Count at Week 12
- (and 25 more...)
|
59 |
All |
18 Years and older (Adult, Senior) |
NCT00988442 |
ACTG A5251 1U01AI068636 10632 |
|
October 2010 |
February 2013 |
February 2013 |
October 2, 2009 |
July 17, 2017 |
July 17, 2017 |
- Alabama Therapeutics CRS
Birmingham, Alabama, United States - Ucsd, Avrc Crs
San Diego, California, United States - Northwestern University CRS (2701)
Chicago, Illinois, United States - (and 13 more...)
|
16 |
NCT00989144 |
Completed |
Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort |
|
|
Observational |
|
- Thai Red Cross AIDS Research Centre
- Walter Reed Army Institute of Research (WRAIR)
|
Other / U.S. Fed |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
1000 |
All |
Child, Adult, Senior |
NCT00989144 |
SEARCH004 |
SEARCH004 |
January 2007 |
October 2008 |
October 2008 |
October 2, 2009 |
October 29, 2009 |
|
- Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
17 |
NCT00993811 |
Completed |
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention |
- Male Circumcision
- HIV Prevention
- HIV Infections
|
- Device: Shang Ring circumcision
|
Interventional |
Phase 1 |
- Weill Medical College of Cornell University
- EngenderHealth
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The efficacy and safety of the ShangRIng device for adult male circumcision in an HIV endemic region in Africa.
- Behavior outcomes (surgical acceptability, satisfaction, problems encountered with the device, compliance with post-surgical instructions, and correct knowledge about the extent of the protective effect of circumcision and safe sex).
|
40 |
Male |
18 Years to 54 Years (Adult) |
NCT00993811 |
0902010241 |
ShangRing |
October 2009 |
February 2010 |
March 2010 |
October 14, 2009 |
December 6, 2010 |
|
- Homa Bay District Hospital
Homa Bay, Kenya
|
18 |
NCT00986999 |
Terminated Has Results |
Effect of Rosuvastatin on Endothelial Function |
- HIV Infections
- Cardiovascular Disease
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Flow Mediated Dilatation (FMD) of the Brachial Artery
- Change in HIV Biomarkers of Immune Activation to Include CD38 and CD69 Expression on T Cells and CD16 and CD69 Expression on Monocytes
- Change in Mitochondrial-specific Oxidative Stress (Mt-specific 8-oxo-dG) and Oxidative Phosphorylation (OXPHOS) Protein/Enzyme Activity [Complex I and Complex IV] Levels
- (and 3 more...)
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT00986999 |
H002 R01HL095135 |
|
September 2009 |
January 2015 |
|
September 30, 2009 |
January 29, 2015 |
January 29, 2015 |
- Hawaii Center for AIDS
Honolulu, Hawaii, United States
|
19 |
NCT01001507 |
Completed |
Integrating Family Planning Services Into HIV Care and Treatment in Nyanza Province, Kenya |
- Unintended Pregnancy
- HIV Infections
|
- Procedure: Integrated family planning/HIV care and treatment services
|
Interventional |
Not Applicable |
- University of California, San Francisco
- Ibis Reproductive Health
- Kenya Medical Research Institute
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Prevalence More Effective Contraception (defined as hormonal methods, intrauterine devices, and permanent methods)
- Pregnancy rate
- Knowledge of contraceptive methods among HIV-positive women
- (and 4 more...)
|
5040 |
All |
18 Years to 45 Years (Adult) |
NCT01001507 |
TFR08-02986 |
|
September 2009 |
October 2011 |
October 2011 |
October 26, 2009 |
December 9, 2013 |
|
- Migori District Hospital
Migori, Kenya
|
20 |
NCT00999739 |
Unknown † |
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults |
- Pneumococcal Vaccines
- HIV
- HIV Infections
|
- Biological: Prevenar and Pneumo23
|
Interventional |
Phase 3 |
- Hospital Universitari Son Dureta
- Hospital Son Llatzer
- Fondo de Investigacion Sanitaria
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Antibody response in terms of antibody concentration at 4,8,48 and 69 weeks of vaccination
- Avidity of the antibodies induced in the two vaccination groups before and at 4 ,8 , 48 and 96 weeks of vaccination
- safety of both vaccines
- (and 2 more...)
|
220 |
All |
18 Years and older (Adult, Senior) |
NCT00999739 |
Maria Penaranda |
|
December 2007 |
April 2008 |
April 2010 |
October 22, 2009 |
November 9, 2009 |
|
- Hospital Son Dureta
Palma de Mallorca, Illes Balears, Spain - Hospital Son Llatzer
Palma de Mallorca, Illes Balears, Spain
|
21 |
NCT00996970 |
Active, not recruiting |
Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons |
|
|
Observational |
|
- Uniformed Services University of the Health Sciences
- Infectious Diseases Clinical Research Program
- National Institute of Allergy and Infectious Diseases (NIAID)
|
U.S. Fed / Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To compare the immunogenicity via anti-hemagglutinin responses following H1N1 vaccination between HIV positive and negative persons.
- To compare the immunogenicity via HAI titer levels, microneutralization seroresponses and titer levels, and cellular responses following H1N1 vaccination between HIV positive and negative persons.
- Among those undergoing vaccination with the seasonal influenza vaccine during the current influenza season, to compare the presence of a positive seroresponse between HIV positive and negative persons
- (and 6 more...)
|
132 |
All |
18 Years to 50 Years (Adult) |
NCT00996970 |
IDCRP-053 |
|
October 2009 |
December 2009 |
December 2018 |
October 16, 2009 |
December 13, 2017 |
|
- Naval Medical Center San Diego
San Diego, California, United States - Walter Reed National Military Medical Center
Bethesda, Maryland, United States - Naval Medical Center Portsmouth
Portsmouth, Virginia, United States
|
22 |
NCT01002612 |
Completed |
Reassessment of the Nutritional Status in Thai Orphans Living With HIV in a Family Style Community |
- HIV Infection
- HIV Infections
|
|
Observational |
|
- Thai Red Cross AIDS Research Centre
- Mahidol University
- South Eastern Area Health Service
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Growth parameters (weight and height), blood lipid levels and dietary intakes
- Morbidity, CD4, HIV-RNA and satisfaction of caregivers and children
|
73 |
All |
4 Years to 15 Years (Child) |
NCT01002612 |
TACHIN003.1 |
TACHIN003-1 |
December 2007 |
August 2008 |
August 2008 |
October 27, 2009 |
November 9, 2009 |
|
- The Thai Red Cross AIDS Research Centre
Pathumwan, Bangkok, Thailand
|
23 |
NCT01001767 |
Completed Has Results |
Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease |
- HIV Infections
- Heart Disease
|
- Drug: Lovaza
- Drug: Placebo
|
Interventional |
Phase 2 |
- University Hospitals Cleveland Medical Center
- The Campbell Foundation
- Case Western Reserve University
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
|
- Change in Flow Mediated Dilation (FMD) of the Brachial Artery
|
35 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01001767 |
AIDS 10-08-24 |
|
April 2009 |
March 2010 |
June 2010 |
October 27, 2009 |
January 7, 2015 |
April 9, 2012 |
- University Hospitals of Cleveland Case Medical Center
Cleveland, Ohio, United States
|
24 |
NCT00988039 |
Completed |
Europe-Africa Research Network for Evaluation of Second-line Therapy |
- Human Immunodeficiency Virus
- HIV
|
- Drug: Aluvia + 2NRTIs
- Drug: Aluvia + raltegravir
- Drug: Aluvia monotherapy
|
Interventional |
Phase 3 |
- Justine Boles
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Medical Research Council
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Good HIV disease control defined as a composite endpoint consisting of all of: - No new WHO stage 4 events - CD4 count >250 cells/mm3 - viral load <10,000 copies/ml or >10,000 copies/ml with no PI resistance mutations
- Good HIV disease control
- Proportion with CD4 cell count >250 cells/mm3
- (and 7 more...)
|
1277 |
All |
12 Years and older (Child, Adult, Senior) |
NCT00988039 |
U.1228.03.004.00021.01 IP_2007_33011_003 ISRCTN37737787 |
EARNEST |
March 2010 |
January 2014 |
January 2014 |
October 1, 2009 |
April 4, 2014 |
|
- AMPATH Centre at Moi Teaching Referral Hospital
Eldoret, Kenya - University of Malawi
Blantyre, Malawi - Mzuzu Central Hospital
Mzuzu, Malawi - (and 11 more...)
|
25 |
NCT00992836 |
Completed Has Results |
Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth |
- HIV Infections
- H1N1 Influenza Virus
|
- Biological: Influenza A (H1N1) 2009 monovalent vaccine
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The Number of Participants Who Had at Least One Adverse Event (AE)
- The Number of Participants Who Had at Least One AE Attributed to the Study Vaccine
- Withholding of Second Vaccine Dose Due to Adverse Reactions Attributed to First Dose
- (and 6 more...)
|
155 |
All |
4 Years to 25 Years (Child, Adult) |
NCT00992836 |
P1088 10840 IMPAACT P1088 |
|
October 2009 |
August 2010 |
August 2010 |
October 9, 2009 |
December 17, 2014 |
February 9, 2012 |
- UAB Pediatric Infectious Diseases CRS
Birmingham, Alabama, United States - Usc La Nichd Crs
Alhambra, California, United States - University of California, UC San Diego CRS
La Jolla, California, United States - (and 34 more...)
|
26 |
NCT00993031 |
Completed Has Results |
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women |
|
- Drug: Lopinavir/ritonavir
- Drug: Efavirenz
- Drug: Zidovudine
- Drug: Lamivudine
|
Interventional |
Phase 3 |
- University of California, San Francisco
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Prevalence of Malaria Defined as Positive Placental Blood Smear
- Prevalence of Malaria Defined as Positive Placental Blood PCR
- Placental Malaria Defined as Positive Placental RDT
- (and 12 more...)
|
389 |
Female |
16 Years and older (Child, Adult, Senior) |
NCT00993031 |
H5741-34342 P01HD059454 2009-141 HS-670 592/ESR/NDA/DID-09/2009 H5741-34342 and 10-02958 |
PROMOTE-PIs |
December 15, 2009 |
July 2013 |
July 2013 |
October 9, 2009 |
December 2, 2017 |
December 2, 2017 |
- Tororo District Hospital
Tororo, Uganda
|
27 |
NCT00992654 |
No longer available |
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
- Human Immunodeficiency Virus (HIV)
|
- Drug: Open Label Treatment Access: Maraviroc
|
Expanded Access |
|
|
Industry |
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00992654 |
A4001096 A4001050 |
|
November 2009 |
February 2010 |
February 2010 |
October 9, 2009 |
November 16, 2010 |
|
|
28 |
NCT00992017 |
Completed Has Results |
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women |
- HIV Infections
- H1N1 Influenza Virus
|
- Biological: Influenza A (H1N1) monovalent vaccine
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The Number of Participants Who Had at Least One Adverse Event (AE)
- The Number of Participants Who Had at Least One AE Attributed to the Study Vaccine
- Withholding of Second Vaccine Dose Due to Adverse Reactions Attributed to First Dose
- (and 7 more...)
|
130 |
Female |
18 Years to 39 Years (Adult) |
NCT00992017 |
P1086 10835 IMPAACT P1086 |
|
October 2009 |
November 2010 |
November 2010 |
October 8, 2009 |
December 30, 2014 |
March 13, 2012 |
- Usc La Nichd Crs
Alhambra, California, United States - University of California, UC San Diego CRS
La Jolla, California, United States - Miller Children's Hosp. Long Beach CA NICHD CRS
Long Beach, California, United States - (and 28 more...)
|
29 |
NCT00990600 |
Completed |
QoL and Adherence to One-pill Once-a-day HAART |
- HIV Infection
- HIV Infections
|
- Other: reduced number of pills
|
Interventional |
Phase 3 |
- A.O. Ospedale Papa Giovanni XXIII
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of adherence to HAART
- QoL (VAS scale) preferences of patients virologic and immunologic outcomes
|
212 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00990600 |
ADONE EUDRACT NUMBER: 2007-007839-33 |
ADONE |
April 2008 |
May 2009 |
May 2009 |
October 7, 2009 |
October 29, 2009 |
|
|
30 |
NCT00993148 |
Completed Has Results |
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 |
- HIV-1 Infection
- HIV Infections
|
- Drug: maraviroc
- Drug: darunavir
- Drug: ritonavir
|
Interventional |
Phase 2 |
- Northwestern University
- Pfizer
- Tibotec, Inc
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Plasma HIV-1 RNA >50
- Percentage of Participants With Virologic Failure or Off Study Treatment Regimen
- Percentage of Participants With Plasma HIV-1 RNA >50 Copies/mL
- (and 6 more...)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00993148 |
MIDAS |
MIDAS |
May 2010 |
April 2013 |
April 2013 |
October 12, 2009 |
September 5, 2014 |
August 19, 2014 |
- Quest Clinical Research
San Francisco, California, United States - University of Miami
Miami, Florida, United States - Northwestern University
Chicago, Illinois, United States - (and 2 more...)
|
31 |
NCT00988780 |
Unknown † |
Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients |
- Immune Reconstitution Inflammatory Syndrome
- HIV
- HIV Infections
|
- Drug: maraviroc
- Drug: Placebo
|
Interventional |
Not Applicable |
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- University of Witwatersrand, South Africa
- Case Western Reserve University
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Time to occurrence of an IRIS event
- Time to occurrence of a severe IRIS event
- Occurrence of either an IRIS event or death
- (and 17 more...)
|
276 |
All |
18 Years and older (Adult, Senior) |
NCT00988780 |
The CADIRIS Study |
CADIRIS |
December 2009 |
March 2013 |
April 2013 |
October 2, 2009 |
November 27, 2012 |
|
- NIH/NIAD
Bethesda, Maryland, United States - Center for AIDS Research. Case Western Reserve University
Cleveland, Ohio, United States - Center for Clinical Epidemiology and Biostatistics. University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States - (and 7 more...)
|
32 |
NCT00990379 |
Unknown † |
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease |
- Parkinson's Disease
- HIV Infections
|
|
Observational |
|
- Salena Killion
- Michael J. Fox Foundation for Parkinson's Research
- KineMed
|
Industry / Other |
- Observational Model: Cohort
|
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT00990379 |
6076 |
|
April 2009 |
February 2016 |
February 2016 |
October 6, 2009 |
March 31, 2015 |
|
- San Francisco General Hospital
San Francisco, California, United States
|
33 |
NCT01000818 |
Completed Has Results |
A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) |
- HIV-1 Infection
- HIV Infections
|
- Drug: MK0518 (Raltegravir)
- Drug: famotidine
- Drug: omeprazole
|
Interventional |
Phase 1 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma Area Under Curve (AUC 0-12 hr ) for Raltegravir
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT01000818 |
0518-054 MK0518-054 2009_681 |
|
June 2008 |
March 2009 |
March 2009 |
October 23, 2009 |
March 21, 2017 |
May 28, 2010 |
|
34 |
NCT00986986 |
Completed Has Results |
Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels |
- HIV Infections
- Dyslipidemia
- Endothelial Dysfunction
|
- Drug: extended release niacin
|
Interventional |
Not Applicable |
- University of Hawaii
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12
- Flow Mediated Vasodilation
- High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12
- HDL
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT00986986 |
ENDO Department of Defense |
|
November 2007 |
April 2010 |
April 2010 |
September 30, 2009 |
December 18, 2012 |
December 18, 2012 |
- University of Hawaii - Hawaii Center for AIDS
Honolulu, Hawaii, United States
|
35 |
NCT01002040 |
Completed |
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV |
- HIV Infections
- H1N1 Influenza
|
|
Interventional |
Phase 4 |
- University of British Columbia
- Canadian Institutes of Health Research (CIHR)
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Occurrence of adverse events (AEs) for days 0-6 after each vaccination
- Occurrence of serious adverse events (SAEs) and other significant health events up to 21 days after each vaccination
- Immunogenicity: Comparison of baseline and post-immunization antibody titres
|
150 |
All |
20 Years to 59 Years (Adult) |
NCT01002040 |
H09-02820 |
|
February 2010 |
July 2010 |
August 2010 |
October 27, 2009 |
April 15, 2015 |
|
- Dalhousie University
Halifax, Nova Scotia, Canada - University of Ottawa / Ottawa Hospital Research Institute
Ottawa, Ontario, Canada - University of Toronto
Toronto, Ontario, Canada - McGill University
Montreal, Quebec, Canada
|
36 |
NCT00985543 |
Completed Has Results |
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses. |
- Acquired Immunodeficiency Syndrome
|
- Drug: lopinavir/ritonavir
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h).
- Adverse Events
|
22 |
All |
18 Years to 65 Years (Adult) |
NCT00985543 |
NCHECR-ENCORE3 |
ENCORE3 |
October 2009 |
January 2010 |
January 2010 |
September 28, 2009 |
March 29, 2011 |
March 29, 2011 |
- St Stephen's Centre, Chelsea and Westminster Hospital
London, United Kingdom
|
37 |
NCT00998621 |
Completed |
ADHEPTA Study: Adherence Questionnaire in Hepatitis C |
- Hepatitis C, Chronic
- HIV Infection
|
- Other: Adherence questionnaire
|
Observational |
|
|
Other |
- Time Perspective: Prospective
|
- Main objective of the study is the development and validation of a Questionnaire measuring treatment adherence in patients with HCV infection.
- Adherence will be measured according to 80/80/80 rule.
- Establish a relationship between adherence, virological response (VR) and Sustained virological response (SVR).
|
1120 |
All |
18 Years and older (Adult, Senior) |
NCT00998621 |
ADH-HEPC-2009-01 |
ADHEPTA |
October 2009 |
September 2010 |
January 2013 |
October 20, 2009 |
October 16, 2015 |
|
- Hospital del Mar
Barcelona, Spain
|
38 |
NCT00988390 |
Completed |
Mothers Living With HIV and Their Adolescent Children |
- Family Relations
- Mental Health
- Physical Health
- (and 3 more...)
|
- Behavioral: Cognitive-behavioral, small-group format sessions
|
Interventional |
Not Applicable |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
543 |
Female |
18 Years and older (Adult, Senior) |
NCT00988390 |
TALKLA-MH068194 5R01MH068194 |
TALK LA |
February 2005 |
June 2008 |
June 2008 |
October 2, 2009 |
November 28, 2016 |
|
|
39 |
NCT01003990 |
Completed Has Results |
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access |
|
- Drug: Atazanavir
- Drug: Atazanavir/Ritonavir
- Drug: Tenofovir/Emtricitabine
- Drug: Lopinavir/ritonavir
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of Participants With Serious Adverse Events (SAEs), Treatment Related SAEs, Treatment Related Adverse Events (AEs), AEs Leading to Discontinuation of Study Therapy, Grade 3 to Grade 4 AEs, Grade 3 to Grade 4 AEs, CDC Class C AIDS Events, or Death
|
710 |
All |
16 Years and older (Child, Adult, Senior) |
NCT01003990 |
AI424-077 |
|
October 2002 |
February 2016 |
February 2016 |
October 29, 2009 |
May 11, 2017 |
May 11, 2017 |
- Phoenix Body Positive, Inc
Phoenix, Arizona, United States - Rand Schrader Clinic
Los Angeles, California, United States - St Francis Memorial Hospital
San Francisco, California, United States - (and 86 more...)
|
40 |
NCT00991289 |
Completed Has Results |
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects |
- HIV Infection
- Hepatitis C Infection
|
- Drug: Nitazoxanide (NTZ)
- Drug: Pegylated interferon alfa-2a (PEG)
- Drug: Ribavirin (RBV)
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Complete Early Virologic Response (cEVR)
- Percentage of Participants With Early Virologic Response (EVR)
- Percentage of Participants With Sustained Virologic Response (SVR)
- (and 8 more...)
|
68 |
All |
18 Years and older (Adult, Senior) |
NCT00991289 |
A5269 10764 ACTG A5269 |
|
January 2010 |
November 2010 |
January 2012 |
October 8, 2009 |
July 7, 2016 |
September 27, 2011 |
- Alabama Therapeutics CRS
Birmingham, Alabama, United States - UCLA CARE Center CRS
Los Angeles, California, United States - Stanford AIDS Clinical Trials Unit CRS
Palo Alto, California, United States - (and 15 more...)
|
41 |
NCT00986063 |
Completed |
Genotype Based Personalized Prescription of Nevirapine |
- Nevirapine Induced Rash
- Nevirapine Induced Hepatitis
- HIV
- (and 3 more...)
|
- Genetic: Genetic test for NVP induced rash
- Other: 3TC/D4T/NVP or 3TC/AZT/NVP
|
Interventional |
Phase 4 |
- Surakameth Mahasirimongkol
- Mahidol University
- Chulalongkorn University
- (and 4 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- To compare the incidences of nevirapine associated rashes in patients who are initiated nevirapine guided by genetic tests (genetic test group) and patients who are initiated nevirapine using standard of care approach (control group).
- To determine the cost-effectiveness of genotyped based personalized prescription of nevirapine.
|
1200 |
All |
18 Years and older (Adult, Senior) |
NCT00986063 |
GENPART |
GENPART |
July 2009 |
July 2012 |
December 2012 |
September 29, 2009 |
April 22, 2013 |
|
- Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
|
42 |
NCT00992069 |
Completed |
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers |
|
- Drug: Efavirenz (EFV)
- Drug: TMC207
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Area under curve (AUC) over 336 hours of TMC207, measured when dosed alone and when dosed together with efavirenz (EFV) 600 mg daily
- Signs or symptoms of toxicity ranked Grade 2 or higher, according to the DAIDS adverse event (AE) grading table
- Maximum observed plasma or serum concentration (Cmax) and oral clearance (CL/F) of TMC207 and AUC, Cmax, and CL/F of the M2 metabolite of TMC207 when dosed alone and when dosed together with EFV 600 mg daily
- (and 2 more...)
|
37 |
All |
18 Years to 65 Years (Adult) |
NCT00992069 |
A5267 10749 ACTG A5267 |
|
December 2009 |
December 2010 |
December 2010 |
October 8, 2009 |
April 4, 2013 |
|
- Ucsf Aids Crs
San Francisco, California, United States - Johns Hopkins Adult AIDS CRS
Baltimore, Maryland, United States - Unc Aids Crs
Chapel Hill, North Carolina, United States - (and 2 more...)
|
43 |
NCT00996528 |
Active, not recruiting |
Neighborhood Alcohol & HIV Prevention in South African Townships (Philani) |
- Fetal Alcohol Syndrome
- HIV
- Nutrition Disorders
|
- Behavioral: Philani Intervention Program
|
Interventional |
Phase 2 |
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- HIV-related transmission acts
- Baby's health status
- Maternal adherence to HIV-related and general health routines
- (and 2 more...)
|
1239 |
Female |
18 Years and older (Adult, Senior) |
NCT00996528 |
Federal Identifier # AA017104 I R0I AA017104-01 |
|
September 2007 |
September 2025 |
September 2025 |
October 16, 2009 |
May 16, 2017 |
|
- Philani Child Health and Nutrition Project, Khayelitsha
Cape Town, South Africa
|
44 |
NCT00987961 |
Completed |
Linking Hospitalized Injection Drug Users to Buprenorphine |
|
|
Interventional |
Phase 3 |
- Butler Hospital
- Boston Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- opioid use
- HIV risk behavior
- reduction in injection-related medical conditions
- reduction in emergency department and hospital utilization
|
147 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00987961 |
1R01DA026223 |
|
September 2009 |
March 2014 |
September 2015 |
October 1, 2009 |
November 11, 2015 |
|
- Boston Medical Center
Boston, Massachusetts, United States
|
45 |
NCT00992433 |
Completed Has Results |
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults |
|
- Biological: Inactivated Influenza H1N1 vaccine
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 10 Days Following the First Dose of H1N1 Vaccine
- Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 21 Days Following the First Dose of H1N1 Vaccine
- Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza H1N1 2009 Virus 10 Days Following the Second Dose of H1N1 Vaccine
- (and 26 more...)
|
192 |
All |
18 Years to 64 Years (Adult) |
NCT00992433 |
09-0073 N01AI80002C |
|
November 2009 |
November 2010 |
November 2010 |
October 9, 2009 |
May 16, 2012 |
November 17, 2011 |
- University of Iowa
Iowa City, Iowa, United States - University of Maryland Baltimore - Institute of Human Virology
Baltimore, Maryland, United States - Saint Louis University
St. Louis, Missouri, United States - (and 3 more...)
|
46 |
NCT00996541 |
Completed |
Support To Reunite Involve and Value Each Other |
- Family Relations
- Runaway Behavior
- Risky Sexual Behavior
- Substance Use
|
- Behavioral: STRIVE family intervention
|
Interventional |
Not Applicable |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Improved residential stability
- Reduced HIV risk behavior
|
302 |
All |
12 Years to 17 Years (Child) |
NCT00996541 |
5R01MH070322-05 |
STRIVE |
September 2004 |
June 2009 |
June 2009 |
October 16, 2009 |
November 9, 2009 |
|
|
47 |
NCT00993694 |
Completed |
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 6 more...)
|
- Drug: chemotherapy
- Drug: dapsone
- Other: medical chart review
- Procedure: assessment of therapy complications
|
Observational |
|
- Vanderbilt University
- National Cancer Institute (NCI)
- Vanderbilt University Medical Center
|
Other / NIH |
|
- Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years
- Major risk factors for developing methemoglobinemia
|
41 |
All |
up to 18 Years (Child, Adult) |
NCT00993694 |
CDR0000652603 P30CA068485 VU-VICC-PED-0916 IRB# 090009 |
|
January 2009 |
December 2009 |
December 2009 |
October 12, 2009 |
April 17, 2017 |
|
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States - Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|